Nationwide Voluntary Recall: Irinotecan

APP Pharmaceuticals has issued a voluntary recall of 5 lots of irinotecan hydrochloride injection (Camptosar) as a precautionary measure. No adverse events related to the recalled products have been reported. The lots recalled: • 870DE00301 • 870CZ00301 • 870DE00101 • 870DE00201 • 870DE00401 APP decided to issue the recall because of customer complaints associated with lot 870DE00301, in which they said they discovered a particulate in the product solution. Investigation of the returned vials confirmed the particulate to be a fungal microbial contaminant. As a precautionary measure and in consultation with the US Food and Drug Administration the lots produced immediately before and after lot 870DE00301 are also being recalled. For complete details, visit http://www.apppharma.com/component/content/article/14-investor-relations/116-news-release-03-25-2011-voluntary-recall-of-irinotecan-hydrochloride-injection.html.